These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 37883217)

  • 21. The role of aldosterone antagonists in the management of resistant hypertension.
    Nishizaka MK; Calhoun DA
    Curr Hypertens Rep; 2005 Oct; 7(5):343-7. PubMed ID: 16157075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biomarkers to Guide Medical Therapy in Primary Aldosteronism.
    Hundemer GL; Leung AA; Kline GA; Brown JM; Turcu AF; Vaidya A
    Endocr Rev; 2024 Jan; 45(1):69-94. PubMed ID: 37439256
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New trials in resistant hypertension: mixed blessing stories.
    Zoccali C; Mallamaci F; De Nicola L; Minutolo R
    Clin Kidney J; 2024 Jan; 17(1):sfad251. PubMed ID: 38186891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. RAS-challenge as a first-look test for detection of primary aldosteronism in patients with treatment-resistant hypertension.
    Beger C; Karg T; Hinrichs JB; Ringe B; Haller H; Meyer BC; Limbourg FP
    Blood Press; 2023 Dec; 32(1):2179340. PubMed ID: 36803263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function.
    Freeman MW; Halvorsen YD; Bond M; Murphy B; Isaacsohn J
    Clin Pharmacol Drug Dev; 2024 Apr; 13(4):410-418. PubMed ID: 38311833
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Revising the Roles of Aldosterone in Vascular Physiology and Pathophysiology: From Electocortin to Baxdrostat.
    Feldman RD; Sanjanwala R; Padwal R; Leung AA
    Can J Cardiol; 2023 Dec; 39(12):1808-1815. PubMed ID: 37734710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. New approaches to blockade of the renin-angiotensin-aldosterone system: mineralocorticoid-receptor blockers exert antihypertensive and renoprotective effects independently of the renin-angiotensin system.
    Nishiyama A; Hasegawa K; Diah S; Hitomi H
    J Pharmacol Sci; 2010; 113(4):310-4. PubMed ID: 20675957
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative Efficacy and Safety of BP-Lowering Pharmacotherapy in Patients Undergoing Maintenance Dialysis: A Network Meta-Analysis of Randomized, Controlled Trials.
    Shaman AM; Smyth B; Arnott C; Palmer SC; Mihailidou AS; Jardine MJ; Gallagher MP; Perkovic V; Jun M
    Clin J Am Soc Nephrol; 2020 Aug; 15(8):1129-1138. PubMed ID: 32675281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preclinical and Early Clinical Profile of a Highly Selective and Potent Oral Inhibitor of Aldosterone Synthase (CYP11B2).
    Bogman K; Schwab D; Delporte ML; Palermo G; Amrein K; Mohr S; De Vera Mudry MC; Brown MJ; Ferber P
    Hypertension; 2017 Jan; 69(1):189-196. PubMed ID: 27872236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
    Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
    Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hypertension and Lorundrostat: Key Discoveries From the TARGET-HTN Trial.
    Irfan H; Ahmed A; Nawani KD
    Curr Probl Cardiol; 2024 Jan; 49(1 Pt C):102144. PubMed ID: 37858848
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological treatment of aldosterone excess.
    Deinum J; Riksen NP; Lenders JW
    Pharmacol Ther; 2015 Oct; 154():120-33. PubMed ID: 26213109
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New approaches in the treatment of hypertension.
    Oparil S; Schmieder RE
    Circ Res; 2015 Mar; 116(6):1074-95. PubMed ID: 25767291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. This is not Dr. Conn's aldosterone anymore.
    Brown NJ
    Trans Am Clin Climatol Assoc; 2011; 122():229-43. PubMed ID: 21686229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of aldosterone synthase inhibition as an add-on therapy in resistant hypertension.
    Karns AD; Bral JM; Hartman D; Peppard T; Schumacher C
    J Clin Hypertens (Greenwich); 2013 Mar; 15(3):186-92. PubMed ID: 23458591
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mineralocorticoid Receptor Antagonists Decrease the Rates of Positive Screening for Primary Aldosteronism.
    Tezuka Y; Turcu AF
    Endocr Pract; 2020 Dec; 26(12):1416-1424. PubMed ID: 33471733
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary aldosteronism: considerations about the evaluation of the aldosterone to renin ratio during canrenone treatment.
    Armanini D; Sabbadin C; Boscaro M
    J Endocrinol Invest; 2021 Sep; 44(9):2009-2010. PubMed ID: 33454931
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of Resistant and Refractory Hypertension.
    Acelajado MC; Hughes ZH; Oparil S; Calhoun DA
    Circ Res; 2019 Mar; 124(7):1061-1070. PubMed ID: 30920924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aldosterone inhibits antifibrotic factors in mouse hypertensive heart.
    Azibani F; Benard L; Schlossarek S; Merval R; Tournoux F; Fazal L; Polidano E; Launay JM; Carrier L; Chatziantoniou C; Samuel JL; Delcayre C
    Hypertension; 2012 Jun; 59(6):1179-87. PubMed ID: 22547442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hypertension and the expanding role of aldosterone.
    Mackenzie SM; Connell J
    Curr Hypertens Rep; 2006 Jun; 8(3):255-61. PubMed ID: 17147925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.